QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) All Versions of this Article: 10/4/643    most recent 15228517-2008-039v1 Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Beauchesne, P. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

LETTER TO THE EDITOR

In Reference to Alexiou et al. (Neuro-Oncology 2008;10:104-105)

Neuro-Oncology, Centre Hospitalier Universitaire (CHU) de Nancy, France

Address correspondence to Patrick Beauchesne, Centre Hospitalier Universitaire: CHU de Nancy, Hopital Central, C.O. Numero 34, 54035 Nancy, France (beauchesneP{at}wanadoo.fr).

Dear Editor,

We read with attention the article "Evaluation of glioma proliferation by ⁹⁹mTc-Tetrofosmin" by Alexiou et al. (Neuro-Oncology 2008;10:104-105). We have significant experience in the use of single-photon emission computed tomography (SPECT) images in the management of malignant glioma patients.^1-3 In our opinion, the published study was too small and underestimated the implications of SPECT images in the management of glioma patients. We would like to clarify this subject by sharing some of our own experiences.

Tetrofosmin scintigraphy has characteristics similar to those of technetium-99m-labeled methoxyisobutyl-isonitrile (⁹⁹mTc-MIBI) scintigraphy. Moreover, its sensitivity and specificity in distinguishing malignant lesions from benign tumors and in discriminating recurrent glioma from radionecrosis are the same as those of ⁹⁹mTc-MIBI scintigraphy.² Moreover, tetrofosmin could be used as a noninvasive marker of glioma proliferative activity, like the sestamibi tracer, but the clinical utility of tetrofosmin needs to be evaluated.⁴

We point out the following:

• ⁹⁹mTc-MIBI SPECT has proved useful in detecting intracranial tumors before therapy, especially neurosurgery, with higher sensitivity and specificity for gliomas than for other cancer histologies (i.e., lymphomas). Moreover, MIBI uptake has been correlated with the grade of malignancy of gliomas.⁴
  
• ⁹⁹mTc-MIBI brain SPECT may be helpful for evaluating the degree of tumor resection of malignant gliomas.⁴
  
• ⁹⁹mTc-MIBI brain SPECT may help in establishing the prognosis of glioma patients at the end of radiation therapy, allowing for adaptations in patient care. These new data should be considered in the design of future clinical studies of malignant glioma therapies as a way to quickly assess the therapies' efficiency.^1,3,4
  

Thank you for sharing these observations with your readers.

Received for publication April 3, 2008. Accepted for publication May 27, 2008.

	References

Top References

 

Beauchesne P, Pedeux R, C Soler. Imaging gliomas with 99mTc-MIBI brain single-photon emission computed tomography. Curr Med Imag Rev. 2006;2: 227-235.[CrossRef]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This Article Full Text (PDF) All Versions of this Article: 10/4/643    most recent 15228517-2008-039v1 Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Beauchesne, P. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

---

Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents